Source-grounded facts extracted from Allogene Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..
“Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.”
Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..
“Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director”
David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..
“Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date”
David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..
“Dr. Chang’s last day of service in these positions will be June 30, 2026.”
Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..
“the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.”
Timothy Moore departed as other_named_officer at Allogene Therapeutics, Inc..
“On January 23, 2025, Allogene Therapeutics, Inc. (the “Company”) and Timothy Moore agreed that Mr. Moore would be leaving his employment with the Company on February 28, 2025.”
Geoffrey Parker changed role as principal accounting officer at Allogene Therapeutics, Inc..
“Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.”
Annie Yoshiyama was appointed as principal accounting officer at Allogene Therapeutics, Inc..
“appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.